Lewis Barrett has been named senior vice president of commercial strategy at Synthetic Biologics, Inc. Mr. Barrett previously served as senior vice president of Commercial Strategy at Synthetic Biologics and served as an advisor to the company since September 2012. Mr. Barrett provides strategic consultation to the global life sciences with a focus on brand and lifecycle strategy, business development, and strategic communications through LL Barrett Biopharmaceutical Consulting, LLC.
Prior to joining the company, Mr. Barrett served as assistant vice president of Established Products at Pfizer and vice president and global business manager of Infectious Diseases at Wyeth Pharmaceuticals and brings expertise in the development, commercialization and launch of infectious disease product candidates. Mr. Barrett successfully led, co-chaired or served on teams that focused on infectious diseases, oncology, transplantation, and hemophilia during his 25 years at Wyeth (acquired by Pfizer in 2009).
Jeffrey Riley, chief executive officer at Synthetic Biologics, said, "We are pleased to welcome Lew to the Synthetic Biologics' team and expect that his extensive experience in the development and commercialization of anti-infectives will be vital to the company as we develop SYN-004 for the prevention of C. difficile infections and monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections."
Synthetic Biologics Names Commercial Strategy VP
Published August 6, 2013
blog comments powered by Disqus